AR133829A1 - CELL PENETRATING AGENTS AND THEIR USES - Google Patents
CELL PENETRATING AGENTS AND THEIR USESInfo
- Publication number
- AR133829A1 AR133829A1 ARP240102462A ARP240102462A AR133829A1 AR 133829 A1 AR133829 A1 AR 133829A1 AR P240102462 A ARP240102462 A AR P240102462A AR P240102462 A ARP240102462 A AR P240102462A AR 133829 A1 AR133829 A1 AR 133829A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- amyloid
- antibody
- nucleic acid
- internalization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación proporciona agentes penetrantes de células que comprenden un módulo de internalización celular y un anticuerpo o fragmento de anticuerpo que se une a antígeno del mismo que se une específicamente al amiloide b humano y método de uso de estos agentes penetrantes de células para tratar pacientes con enfermedades relacionadas con beta amiloide, incluyendo la Miositis por cuerpos de inclusión (MCI). Reivindicación 1: Un agente penetrante de células (APC) anti-péptido Amiloide b (Ab) que comprende: (i) un módulo de internalización celular (MIC) y (ii) un anticuerpo que se une específicamente al péptido Amiloide b (Ab). Reivindicación 72: Una composición farmacéutica que comprende el APC anti-Ab de una cualquiera de las reivindicaciones 1 - 71 y un portador o diluyente farmacéuticamente aceptable. Reivindicación 73: Un ácido nucleico que codifica al menos una porción del APC anti-Ab de una cualquiera de las reivindicaciones 1 - 71. Reivindicación 78: Un vector que comprende el ácido nucleico de una cualquiera de las reivindicaciones 73 - 77 unido de manera operativa a una o más secuencias reguladoras para efectuar la expresión en una célula de mamífero del agente penetrante de células de una cualquiera de las reivindicaciones 1 a 71. Reivindicación 81: Una célula huésped transformada con el vector de una cualquiera de las reivindicaciones 78 - 80. Reivindicación 82: Una célula huésped que comprende el ácido nucleico de una cualquiera de las reivindicaciones 73 - 77. Reivindicación 85: Un método de unión una proteína Ab intracelular en una célula, en donde el método comprende: poner en contacto el APC anti-Ab de una cualquiera de las reivindicaciones 1 a 71 con la célula, dando como resultado de ese modo la internalización de, y transferencia al citosol de, como mínimo, un fragmento de unión a antígeno del anticuerpo.This disclosure provides cell-penetrating agents comprising a cell internalization module and an antibody or antibody fragment binding to an antigen thereof that specifically binds to human amyloid b, and a method of using these cell-penetrating agents to treat patients with beta-amyloid-related diseases, including inclusion body myositis (IBM). Claim 1: An anti-amyloid b peptide (Ab) cell-penetrating agent (CPA) comprising: (i) a cell internalization module (CPM) and (ii) an antibody that specifically binds to the amyloid b peptide (Ab). Claim 72: A pharmaceutical composition comprising the anti-Ab CPA of any one of claims 1-71 and a pharmaceutically acceptable carrier or diluent. Claim 73: A nucleic acid encoding at least a portion of the anti-Ab APC of any one of claims 1-71. Claim 78: A vector comprising the nucleic acid of any one of claims 73-77 operatively linked to one or more regulatory sequences to effect expression in a mammalian cell of the cell-penetrating agent of any one of claims 1-71. Claim 81: A host cell transformed with the vector of any one of claims 78-80. Claim 82: A host cell comprising the nucleic acid of any one of claims 73-77. Claim 85: A method of attaching an intracellular Ab protein to a cell, wherein the method comprises: contacting the anti-Ab APC of any one of claims 1-71 with the cell, thereby resulting in the internalization of, and transfer to the cytosol of, at least an antigen-binding fragment of the antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363538600P | 2023-09-15 | 2023-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133829A1 true AR133829A1 (en) | 2025-11-05 |
Family
ID=93010600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240102462A AR133829A1 (en) | 2023-09-15 | 2024-09-13 | CELL PENETRATING AGENTS AND THEIR USES |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR133829A1 (en) |
| TW (1) | TW202530246A (en) |
| WO (1) | WO2025059487A2 (en) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| ATE420178T1 (en) | 1992-08-21 | 2009-01-15 | Univ Bruxelles | IMMUNOGLOBULINS WITHOUT LIGHT CHAIN |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (en) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Strong homologous promoter from hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DE60036082T2 (en) | 1999-02-05 | 2008-06-12 | Samsung Electronics Co., Ltd., Suwon | METHOD AND DEVICE FOR RECONSTRUCTING TEXTURE IMAGES |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP4344325B2 (en) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Novel neomycin phosphotransferase gene and method for selecting highly producing recombinant cells |
| DE10338531A1 (en) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for recloning production cells |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| AU2006208226A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PT2099823E (en) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Variant target binding agents and uses thereof |
| PL2104682T3 (en) | 2007-01-11 | 2017-03-31 | Michael Bacher | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
| PT2126093E (en) | 2007-03-02 | 2012-12-03 | Boehringer Ingelheim Pharma | Improvement of protein production |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| EP2031064A1 (en) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for increasing protein titres |
| WO2019040612A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| DE102019132785A1 (en) | 2018-12-05 | 2020-06-10 | Magna BOCO GmbH | HINGE ARRANGEMENT WITH SEPARATE SPRING ARRANGEMENT |
| KR20220084095A (en) | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | Anti-beta-amyloid antibody for the treatment of Alzheimer's disease |
| CA3188763A1 (en) | 2020-09-10 | 2022-03-17 | Ludwig-Maximilians-Universitat Munchen | Engineered aav vectors |
| US20240301042A1 (en) * | 2021-03-23 | 2024-09-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Selective targeting of oligomeric b-amyloid |
| AU2022428997A1 (en) * | 2021-12-31 | 2024-08-15 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
-
2024
- 2024-09-13 AR ARP240102462A patent/AR133829A1/en unknown
- 2024-09-13 WO PCT/US2024/046654 patent/WO2025059487A2/en active Pending
- 2024-09-13 TW TW113134888A patent/TW202530246A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025059487A2 (en) | 2025-03-20 |
| TW202530246A (en) | 2025-08-01 |
| WO2025059487A3 (en) | 2025-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000280A (en) | STABLE FORMULATIONS OF ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1) AND METHODS FOR THEIR USE | |
| BR112021000807A8 (en) | USES OF AN IMMUNOGLOBULIN G DEGRADING ENZYME POLYPEPTIDE, USE OF A NUCLEIC ACID SEQUENCE, USE OF AN EXPRESSION VECTOR, PACK OR KIT, AND USE OF A PACK OR KIT | |
| PE20251185A1 (en) | CONDITIONALLY ACTIVATED RESTRICTED BINDING PROTEINS | |
| CL2022000094A1 (en) | Anti-cd63 antibodies, conjugates and their uses (divisional of application no. 202002965) | |
| MX2023008115A (en) | Chimeric receptor therapy. | |
| BR0008161A (en) | Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell | |
| CL2022003715A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2023003039A (en) | AGENTS AND METHODS FOR DELIVERY DIRECTED TO CELLS. | |
| CL2023000121A1 (en) | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses | |
| AR017973A1 (en) | PHARMACEUTICAL ISOTONIC FORMULATION, USE OF SUCH FORMULATION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE THERAPY OF AN AUTOIMMUNE DISEASE, AND METHOD FOR IMPROVING THE STORAGE OF AN ANTIBODY | |
| AR128060A1 (en) | CONDITIONALLY ACTIVATED ANTIGEN-BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | |
| AR125351A1 (en) | COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF PNPLA3 | |
| MX2021015501A (en) | ANTIBODIES AND METHODS OF USE. | |
| ES2061521T3 (en) | PROTEINS WITH GLUTATION-S-TRANSFERASE ACTIVITY, DNA SEQUENCES, ANTIBODIES, POXVIRUSES AND MEDICINES FOR THE PREVENTION OF EQUISTOSOMIASIS. | |
| AR133829A1 (en) | CELL PENETRATING AGENTS AND THEIR USES | |
| AR129303A1 (en) | MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1 AND THEIR MEDICINAL USE | |
| CL2025002617A1 (en) | Antibody-drug conjugates administered subcutaneously for use in the treatment of cancer | |
| BR112022020871A2 (en) | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS | |
| JP6840086B2 (en) | Isolated fibrinogen-derived peptides and fragments thereof for use as drugs, especially in cutaneous inflammatory diseases | |
| AR014884A1 (en) | USE OF AN IMMUNOGENIC ANGIOTENSIN CONJUGATE AND PHARMACEUTICAL COMPOSITION | |
| AR133834A1 (en) | CELL PENETRATION AGENTS AND THEIR USES | |
| PE20250754A1 (en) | RNAI constructs and methods to inhibit FAM13A expression | |
| CO2023010473A2 (en) | Compositions and methods of cell therapy to modulate tgf-b signaling | |
| MX2023000004A (en) | Formulations for promoting hydration and methods of use thereof. | |
| BR112022014821A2 (en) | TREATMENT INVOLVING ANTIGEN VACCINATION AND BINDING AGENTS THAT BIND TO PD-L1 AND CD137 |